- Volatility is at a recent 2 week high. A high volatility of stock movement indicates uncertainty.
- MACD is crossing MACD signal line at 0.3. MACD crossing signal line is bullish signal.
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes fromFinra
Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that Chief Executive Officer, Barry Greene, will discuss the Company’s progress in becoming a leader in brain health in a corporate presentation at the 39th Annual J.P. Morgan Healthcare Conference. As part of the presentation, Mr. Greene will highlight the Company’s planned portfo...
Upgrades * B of A Securities upgraded the previous rating for Expedia Group Inc (NASDAQ:EXPE) from Neutral to Buy. For the third quarter, Expedia Group had an EPS of $0.24, compared to year-ago quarter EPS of $3.37. At the moment, the stock has a 52-week-high of $134.09 and a 52-week-low of $40.76. Expedia Group closed at $132.40 at the end of the last trading period. * According to Evercore ISI Group, the prior rating for Zimmer Biomet Holdings Inc (NYSE:ZBH) was changed from In-Line to Outp...
Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 10:50 a.m. ET.
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 817 13F filings submitted by hedge funds and prominent investors. These filings show these funds’ portfolio positions as of September 30th, 2020. […]
Sage Therapeutics, Inc. ( NASDAQ:SAGE ) shareholders will have a reason to smile today, with the analysts making...
Each company has suffered a clinical failure recently, but this team-up could do good things for both.
This biotech giant is getting desperate to generate sales growth. Should investors be hopeful for a potential turnaround?
Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating brain disorders, today announced that, as part of the Company’s plan to accelerate growth and leverage the talents of the leaders in the brain health space, Barry Greene has been appointed chief executive officer. Mr. Greene, who most recently served as president of Alnylam Pharmaceuticals, Inc., from 2007 to September 2020, a...